Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis.

@article{Zhang2016IncidenceAR,
  title={Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis.},
  author={Xiaoying Zhang and Yuge Ran and Yongjie Shao and Kunjie Wang and Yuanxue Zhu},
  journal={British journal of clinical pharmacology},
  year={2016},
  volume={81 1},
  pages={
          33-40
        }
}
AIMS Aflibercept is an engineered humanized vascular endothelial growth factor (VEGF)-targeted agent. Severe infections are serious adverse event associated with aflibercept. However, the contribution of aflibercept to infection is still unknown. We thus conducted this meta-analysis to investigate the overall incidence and risk of developing severe infections in cancer patients treated with aflibercept. METHODS Electronic databases including PubMed, Embase and abstracts presented at American… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 11 times. VIEW TWEETS

References

Publications referenced by this paper.
SHOWING 1-10 OF 26 REFERENCES

A phase II multicentre study of ziva fl ibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced / metastatic non - squamous non - small cell lung cancer

  • R Ramlau, V Gorbunova, +11 authors G Scagliotti
  • Br J Cancer
  • 2014

A fl ibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non - small - cell lung cancer : a randomized , controlled phase III trial

  • NB Leighl, LE Raez, +14 authors RS Herbst
  • J Clin Oncol
  • 2012

Similar Papers

Loading similar papers…